Robert E. Tarone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert E. Tarone has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Joseph K. McLaughlin
1 shared publicationWilliam J. Blot
1 shared publication
Latest Publications
- Open Access
- 1 April 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (4) , A153
DDT and Breast Cancer
- 1 April 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (4) , A153
Open AccessDDT and Breast Cancer
- 1 September 2006
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 17 (5) , 588-590
Breast Cancer Trends Among Young Women in the United States
It has been suggested that exposures associated with industrialization have increased breast cancer risk among young women in recent decades in the United States despite data demonstrating declining breast cancer mortality in birth cohorts born after 1945. Trends for in situ and invasive breast cancer incidence rates from 1975 through 2002 among white and black U.S. women ages 20 to 49 are evaluated by decade of age using linear regression analyses. Despite increasing rates of in situ breast cancer after 1980 reflecting increased use of mammography, invasive breast cancer rates declined for both white and black women under age 50. These declines are consistent with a decrease in birth cohort risk of breast cancer for women born after 1945. Invasive breast cancer incidence rates are not increasing in young U.S. women despite increases in mammography and trends in known risk factors (eg, reproductive factors) that would predict increasing risk.
- 1 September 2006
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 17 (5) , 588-590
Breast Cancer Trends Among Young Women in the United States
It has been suggested that exposures associated with industrialization have increased breast cancer risk among young women in recent decades in the United States despite data demonstrating declining breast cancer mortality in birth cohorts born after 1945. Trends for in situ and invasive breast cancer incidence rates from 1975 through 2002 among white and black U.S. women ages 20 to 49 are evaluated by decade of age using linear regression analyses. Despite increasing rates of in situ breast cancer after 1980 reflecting increased use of mammography, invasive breast cancer rates declined for both white and black women under age 50. These declines are consistent with a decrease in birth cohort risk of breast cancer for women born after 1945. Invasive breast cancer incidence rates are not increasing in young U.S. women despite increases in mammography and trends in known risk factors (eg, reproductive factors) that would predict increasing risk.
- 1 September 2005
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 16 (5) , 710-711
Circadian Disruption and Breast Cancer
- 1 September 2005
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 16 (5) , 710-711
Circadian Disruption and Breast Cancer
- 1 January 2004
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 11 (1) , 17-25
Nonselective Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Bleeding: Relative and Absolute Risk Estimates From Recent Epidemiologic Studies
Gastrointestinal bleeding (GIB) is known to be associated with use of nonselective nonaspirin nonsteroidal anti-inflammatory drugs (NNANSAIDs), but it is less clear whether and to what extent variation in GIB risk exists according to the characteristics of exposure. To assess the consistency of data on the relative and absolute risks of GIB among NNANSAID users, we reviewed epidemiologic studies conducted around the world for data on NNANSAID use categorized by dose, timing, and type of exposure. US mortality rates for GIB were obtained and used to estimate national rates of GIB death attributable to NNANSAID use in the 1990s. The average relative increase in risk of GIB among NNANSAID users was found to be fourfold or slightly higher, regardless of the demographic characteristics of the studied population. There were approximately twofold increases associated with over-the-counter doses and sixfold or higher increases at heavy prescription levels. Variation in risk exists by type of NNANSAID, although differences by preparation seem at least partly dose-related. GIB risk declines following cessation of NNANSAID use, with current rather than prior cumulative exposure the key determinant of risk. The baseline rate of GIB in all studied populations rises markedly with advancing age. Annual hospitalization rates for GIB exceed one per 1000 among the elderly, with the large majority of cases occurring among persons age 65 years and older. NNANSAID use may account for nearly 34% of all GIB cases in the United States, and may have resulted in over 32,000 GIB hospitalizations and 3200 GIB deaths per year in the 1990s.
- 1 January 2004
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 11 (1) , 17-25
Nonselective Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Bleeding: Relative and Absolute Risk Estimates From Recent Epidemiologic Studies
Gastrointestinal bleeding (GIB) is known to be associated with use of nonselective nonaspirin nonsteroidal anti-inflammatory drugs (NNANSAIDs), but it is less clear whether and to what extent variation in GIB risk exists according to the characteristics of exposure. To assess the consistency of data on the relative and absolute risks of GIB among NNANSAID users, we reviewed epidemiologic studies conducted around the world for data on NNANSAID use categorized by dose, timing, and type of exposure. US mortality rates for GIB were obtained and used to estimate national rates of GIB death attributable to NNANSAID use in the 1990s. The average relative increase in risk of GIB among NNANSAID users was found to be fourfold or slightly higher, regardless of the demographic characteristics of the studied population. There were approximately twofold increases associated with over-the-counter doses and sixfold or higher increases at heavy prescription levels. Variation in risk exists by type of NNANSAID, although differences by preparation seem at least partly dose-related. GIB risk declines following cessation of NNANSAID use, with current rather than prior cumulative exposure the key determinant of risk. The baseline rate of GIB in all studied populations rises markedly with advancing age. Annual hospitalization rates for GIB exceed one per 1000 among the elderly, with the large majority of cases occurring among persons age 65 years and older. NNANSAID use may account for nearly 34% of all GIB cases in the United States, and may have resulted in over 32,000 GIB hospitalizations and 3200 GIB deaths per year in the 1990s.